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RCI was classified in three categories 0 to 2 , 3 to 4 and 5 and 
higher. For this purpose we used Kaplan-Meier method and 
Cox proportional hazards modeling 
 
Results: Finally 550 patients with prostate cancer were 
included, with median age of 70 years old (47-85), Mean 
follow-up time was 136.8 months, between 5,6 and 245,8 
months. D’Amico risk classification distribution was for low 
risk, mediun and high 20.4%, 36,5% and 43,1% respectively. 
RCI distribution categories was as follows 61,5%, 21,8 and 
16,7%. Survival analysis showed significant differences 
(p<0.001) between RCI groups at 5 and 10 years. Survival 
probability was 98,2 and 88,5% ; 95% and 79,6% ; and 52,2% 
and 8,9% was respectively for each RCI category. 
 
Conclusion: RCI allowed for more accurate identification of 
men at highest risk for other cause mortality. 
Our results are in concordance with original RCI .This revised 
index may be used to aid medical decision making and 
personalized medecine for men with prostate cancer.  
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Purpose or Objective: The definition of the clinical target 
volume (CTV) for salvage radiotherapy after prostatectomy is 
based on clinical and pathologic variables of the tumor and 
consensus guidelines. Multiparametric-MRI is recommended 
to evaluate pelvic recurrences after radical prostatectomy 
when the PSA is low (0.2-2 ng/ml) but the benefit of planning 
individualised radiation treatment based on the results of MRI 
is unknown. We analysed whether all suspicious lesions 
detected with pelvic multiparametric MRI were included in 
the clinical target volume defined according to four current 
guidelines and we determined the percentage of missing 
target if this radiological information was lost. 
 
Material and Methods: We retrospectively reviewed the 
clinical records and multiparametric MRI studies of 70 
patients with PSA recurrence after radical prostatectomy. 
Salvage radiotherapy of at least the prostate bed was 
indicated in all cases. On the simulation CT scan of 33 
patients who had visible tumor recurrence in the MRI study, 
we delineated four different CTV according to RTOG, EORTC, 
PMH and FROGG consensus guidelines for postoperative 
prostate bed irradiation. We delineated a relapse CTV which 
included the radiological tumor recurrence plus 5 mm. For 
the PTV, we added a 5 mm margin. We compared volume size 
of the CTV and determined the percentage of geographically 
missed target (relapse PTV not included / relapse PTV).  
 
Results: Multiparametric-MRI was positive in 33/70 patients. 
Local recurrence occurred in 27 patients, mainly in the 
perianastomotic area (19). Mutiparametric-MRI detected 
positive lymph nodes in 7 patients, mostly in the external 
iliac region. The mean size of the lymph nodes was 10 mm 
(range 8-16 mm). The mean volumes of the CTV delineated 
according to the EORTC, RTOG, PMH and FROGG consensus 
were 81.5, 100.7, 109.3 and 99.7 cc, respectively. In 2 out of 
33 cases, the recurrence depicted in the pelvic MRI was not 
totally enclosed in the CTV, independently of the consensus 
guidelines used. The missed recurrences were located in the 
left retrovesical region (patient 1) and at the level of the 
penile bulb (patient 2) . The volumes of the relapsed PTV 
were 23.4 and 14.9 cc, respectively. The percentages of 
relapse PTV out of the PTV created according to each 
guideline were 41%, 59%, 44 and 44% in patient 1 and 44%, 
39%, 39% and 41% in patient 2. In 7 out of 70 patients (10%), 
lymph node recurrence would have been missed if we had 
only considered salvage prostate bed irradiation.  
 
Conclusion: Using current guidelines for CTV definition for 
salvage radiotherapy after prostatectomy, we found that the 
local recurrences depicted in the pelvic multiparametric MRI 
were totally covered in most patients. Multiparametric-MRI 
may help tailor local and lymph node CTV and identify lesions 
to treat with a higher dose 
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Purpose or Objective: To report the toxicity and preliminary 
biochemical outcomes with high-dose intensity-modulated 
radiation therapy (IMRT) to a dose of 82.8Gy in patients 
prostate cancer. 
 
Material and Methods: Between April 2002 and December 
2013, 757 patients with biopsy proven prostate cancer were 
treated with high-dose IMRT. While 398 patients received a 7 
or 8- field -IMRT -sliding window- technique up to a median 
total dose to the prostate of 77.4 Gy/1.8Gy, 359 patients 
were treated with a 2 arc-Volumetric Modulated ArcTherapy 
(VMAT) plans up to a median total dose to the prostate of 
82.0Gy/ 1.8Gy. In 264 high-risk prostate cancer patients the 
pelvic node region was treated to incorporate the nodes at 
risk. Total doses of 50.4Gy were prescribed to the pelvis. In 
29 % of SW patients and 23% of VMAT patients an additional 
boost of 5 to 16Gy was administered in cases of MRI-staged 
lymph node metastases. Acute and late toxicities were 
prospectively scored by the RTOG/ LENT SOMA morbidity 
grading scales (until 2009) and a modified CTCAEv3.0 score 
(since 2009), respectively. Biochemical failure was defined 
according to the Phoenix definition of nadir + 2ng/ml. The 
median follow- up time was 65 months (range,12-151 
months). 
 
Results: The IMRT dose distribution provided excellent PTV 
coverage and satisfying protection of all the organs at risk, 
with less than 2% of all patients experiencing grade (G) 3 
toxicities, G4 toxicities were not observed at all. In total 40.3 
/ 11 / 1.1% of patients developed acute G1/ 2/ 3 
genitourinary (GU) toxicities. 28%/ 3.1% of patients 
experienced acute G1/ 2 gastrointestinal (GI) side effects, no 
patient developed acute > G2 gastrointestinal symptoms. 
Late GU- and GI toxicity was mild with > 85% of the patients 
free from any GU/GI toxicity during follow-up and no time 
trend to increased rates or to higher grade of GU/GI- 
toxicity. Maximum late GU toxicities were G1/ 2/ 3 for 10/ 
2.5/ 1.6% of patients, respectively. Maximum late GI 
toxicities were G1/2 for 4.9 / 0.4%of patients. The 5-year 
freedom from biochemical failure (FFBF) was 87.8%for all 
patients and 95, 79.9 and 83.4% for low-, intermediate-, and 
high-risk disease. 
 
Conclusion: These data demonstrate that escalated -dose 
IMRT is a well tolerated technique in prostate cancer patients 
and the preliminary excellent biochemical control rates are 
encouraging.  
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